A double-blind clinical trial of iopamidol versus metrizamide for lumbosacral myelography.
A double-blind study was performed to compare metrizamide with the new iodinated water-soluble nonionic contrast medium, iopamidol, for conventional and computerized tomography lumbosacral myelography. Both contrast agents were used in 30 patients, and were equivalent in terms of image quality and clinical accuracy. Headaches and nausea were less severe using iopamidol. The most striking difference was found in adverse neurobehavioral reactions and associated electroencephalographic abnormalities, which were noted in 17% of the metrizamide group but were not seen with the use of iopamidol. Iopamidol appears to be superior to metrizamide for intrathecal applications. An explanation of the differential neurotoxicity is provided.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007479:Iopamidol; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D008161:Lumbosacral Region; D008793:Metrizamide / Q000009:adverse effects; D009192:Myelography / Q000592:standards*; D014057:Tomography, X-Ray Computed
D007483:Iothalamic Acid; D007479:Iopamidol; D008793:Metrizamide